drugset / Trial / NCT04176653
Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary purpose of this study is to determine the safety and tolerability of SLN124 for the treatment of non-transfusion-dependent (NTD) β-thalassaemia and low risk myelodysplastic syndrome.
Timeline
- Start
- 2019-08-20
- Primary completion
- 2021-09-30
- Completion
- 2021-10-14
Outcome
Outcome not reported
Stopped: “Study stopped prior to subject administered first dose, due to COVID-19”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SLN124 | Small interfering RNA (siRNA) | 0.3 mg/kg | — |
| Subject | SLN124 | Small interfering RNA (siRNA) | 1 mg/kg | — |
| Subject | SLN124 | Small interfering RNA (siRNA) | 3 mg/kg | — |
| Subject | SLN124 | Small interfering RNA (siRNA) | 10 mg/kg | — |